Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy

Fig. 2

Efficacy of PF-06438179/GP1111 and infliximab-EU. a Difference (95% CI) in week 14 ACR20 response between PF-06438179/GP1111 and infliximab-EU using NRI and symmetric equivalence margin. b Difference (90% CI) in week 14 ACR20 response between PF-06438179/GP1111 and infliximab-EU using NRI and asymmetric margin. c ACR20, ACR50, and ACR70 response rates by visit (ITT population). d Mean (± SE) change from baseline in DAS28-CRP by visit (ITT population). e Mean (± SE) change from baseline in HAQ-DI by visit (ITT population). ACR20/50/70 American College of Rheumatology criteria for ≥ 20%/50%/70% clinical improvement, DAS28-CRP Disease Activity Score in 28 joints, four components based on C-reactive protein, HAQ-DI Health Assessment Questionnaire Disability Index; Infliximab-EU Infliximab sourced from the European Union, ITT Intention to treat, NRI Nonresponder imputation, PP Per protocol

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us